PTI Protherics

    RNS Number : 8912G
  Protherics PLC
  28 October 2008
   

    Protherics PLC

    Notification of Directors' Interests


    London, UK; Brentwood, TN, US: 28 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, in accordance with the FSA Disclosure and Transparency Rules, announces that, on 23 October
2008, pursuant to the conversion of all outstanding six per cent. unsecured convertible loan notes 2010 of Protherics, the following
ordinary shares (the "Shares") were allotted to Directors of Protherics PLC:

 Director       Nominal Value of Loan  Shares allotted share capital  % issued
                      Notes converted
 Andrew Heath                 �24,242                         96,968    0.028%
 Stuart Wallis                �60,606                        242,424    0.069%

    In accordance with the Loan Note Instrument, the Shares were allotted at a price of 25 pence per share.

    Following the above allotment of Shares, their interests in the ordinary share capital of the Company are as follows:

                No. Shares  % issued share capital
 Andrew Heath      516,778                  0.148%
 Stuart Wallis     809,113                  0.231%

    | Ends |

    For further information please contact:

 Protherics 
 Nick Staples, Director of Corporate Affairs  +44 (0) 7919 480510  
 Julie Vickers, Company Secretary             +44 (0)1928 518010

 Financial Dynamics - press enquiries
 London: Ben Atwell, Lara Mott                +44 (0) 20 7831 3113 
 New York: John Capodanno                     +1 212 850 5600

    Or visit  www.protherics.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RDSMPBPTMMTTBJP

Grafico Azioni Protherics (LSE:PTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Protherics (LSE:PTI)
Storico
Da Giu 2023 a Giu 2024